List of Excipients in API TUCATINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing TUCATINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| SEAGEN INC | TUKYSA | tucatinib | 51144-001 | COPOVIDONE K25-31 | 2032-10-12 |
| SEAGEN INC | TUKYSA | tucatinib | 51144-001 | CROSPOVIDONE | 2032-10-12 |
| SEAGEN INC | TUKYSA | tucatinib | 51144-001 | FERRIC OXIDE YELLOW | 2032-10-12 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for TUCATINIB
Excipient focus: COPOVIDONE K25-31
TUCATINIB drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
TUCATINIB drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
TUCATINIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
TUCATINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
TUCATINIB drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
TUCATINIB drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
TUCATINIB drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM CHLORIDE
TUCATINIB drug variants containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
TUCATINIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
TUCATINIB drug variants containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
TUCATINIB drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
TUCATINIB drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
TUCATINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SEAGEN INC | tucatinib | 51144-001 |
| >Company | >Ingredient | >NDC |
TUCATINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
